{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T23:35:46Z","timestamp":1794612946884,"version":"4.9.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010029","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","award":["tscy20170519"],"award-info":[{"award-number":["tscy20170519"]}],"id":[{"id":"10.13039\/501100010029","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ijbiomac.2024.136477","type":"journal-article","created":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T02:15:50Z","timestamp":1728699350000},"page":"136477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"P4","title":["CRM197-scaffolded vaccines designed by epitope grafting ameliorate cognitive decline in an Alzheimer's disease model"],"prefix":"10.1016","volume":"281","author":[{"given":"Weiwei","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurong","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyuan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinli","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijbiomac.2024.136477_bb0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.neuron.2006.09.016","article-title":"A hundred years of Alzheimer\u2019s disease research","volume":"52","author":"Hardy","year":"2006","journal-title":"Neuron"},{"issue":"8003","key":"10.1016\/j.ijbiomac.2024.136477_bb0010","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/d41586-024-00756-8","article-title":"Researchers call for a major rethink of how Alzheimer\u2019s treatments are evaluated","volume":"627","author":"Landhuis","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2024.136477_bb0015","first-page":"2(3)","article-title":"China Alzheimer\u2019s disease: facts and figures","volume":"2023","author":"Xiao","year":"2023","journal-title":"Human Brain."},{"issue":"9","key":"10.1016\/j.ijbiomac.2024.136477_bb0020","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nrd3505","article-title":"The amyloid cascade hypothesis for Alzheimer\u2019s disease: an appraisal for the development of therapeutics","volume":"10","author":"Karran","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ijbiomac.2024.136477_bb0025","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Hardy GAH: Alzheimer\u2019s disease: the amyloid cascade hypothesis","volume":"256","author":"John","year":"1992","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.136477_bb0030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1474-4422(23)00449-0","article-title":"Dementia research in 2023: the year of anti-amyloid immunotherapy","volume":"23","author":"Delrieu","year":"2024","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.136477_bb0035","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","article-title":"Lecanemab, aducanumab, and gantenerumab - binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer\u2019s disease","volume":"20","author":"Soderberg","year":"2023","journal-title":"Neurotherapeutics"},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.136477_bb0040","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/13543784.2023.2178414","article-title":"Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer disease","volume":"32","author":"Vitek","year":"2023","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.136477_bb0045","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40035-022-00292-3","article-title":"Immunotherapy for Alzheimer\u2019s disease: targeting beta-amyloid and beyond","volume":"11","author":"Song","year":"2022","journal-title":"Transl. Neurodegener."},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.136477_bb0050","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/156720509787602852","article-title":"Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders","volume":"6","author":"Vellas","year":"2009","journal-title":"Curr. Alzheimer Res."},{"issue":"5","key":"10.1016\/j.ijbiomac.2024.136477_bb0055","first-page":"663","article-title":"AN-1792 (Elan)","volume":"2","author":"Thatte","year":"2001","journal-title":"Curr. Opin. Investig. Drugs"},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.136477_bb0060","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2217\/imt.10.94","article-title":"Therapeutic potential of vaccines for Alzheimer\u2019s disease","volume":"3","author":"Shah","year":"2011","journal-title":"Immunotherapy"},{"issue":"3","key":"10.1016\/j.ijbiomac.2024.136477_bb0065","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/jnc.12202","article-title":"Alzheimer\u2019s Abeta42 and Abeta40 peptides form interlaced amyloid fibrils","volume":"126","author":"Gu","year":"2013","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.136477_bb0070","article-title":"Current peptide vaccine and immunotherapy approaches against Alzheimer\u2019s disease","volume":"115","author":"Parrocha","year":"2023","journal-title":"Pept Sci (Hoboken)."},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.136477_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00321","article-title":"Disentangling tau: one protein, many therapeutic approaches","volume":"21","author":"Lane-Donovan","year":"2024","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.136477_bb0080","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14283\/jpad.2018.45","article-title":"AADvac1, an active immunotherapy for Alzheimer\u2019s disease and non Alzheimer tauopathies: an overview of preclinical and clinical development","volume":"6","author":"Novak","year":"2019","journal-title":"J. Prev Alzheimers Dis."},{"issue":"9","key":"10.1016\/j.ijbiomac.2024.136477_bb0085","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2217\/imt-2016-0019","article-title":"Tau-based therapeutics for Alzheimer\u2019s disease: active and passive immunotherapy","volume":"8","author":"Panza","year":"2016","journal-title":"Immunotherapy"},{"issue":"10","key":"10.1016\/j.ijbiomac.2024.136477_bb0090","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/s41593-020-0687-6","article-title":"Synergy between amyloid-beta and tau in Alzheimer\u2019s disease","volume":"23","author":"Busche","year":"2020","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ijbiomac.2024.136477_bb0095","doi-asserted-by":"crossref","first-page":"28912","DOI":"10.1038\/srep28912","article-title":"Alzheimer\u2019s disease Advax(CpG)- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and abeta pathological molecules","volume":"6","author":"Davtyan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2024.136477_bb0100","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41541-019-0118-4","article-title":"Q\u00df virus-like particle-based vaccine induces robust immunity and protects against tauopathy","volume":"4","author":"Maphis","year":"2019","journal-title":"NPJ Vaccines."},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.136477_bb0105","article-title":"Yeast-based virus-like particles as an emerging platform for vaccine development and delivery","volume":"11","author":"Srivastava","year":"2023","journal-title":"Vaccines (Basel)."},{"key":"10.1016\/j.ijbiomac.2024.136477_bb0110","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41541-017-0030-8","article-title":"Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer\u2019s and cat allergy","volume":"2","author":"Zeltins","year":"2017","journal-title":"NPJ Vaccines"},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.136477_bb0115","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.imlet.2015.09.002","article-title":"Norovirus P particle: an excellent vaccine platform for antibody production against Alzheimer\u2019s disease","volume":"168","author":"Fu","year":"2015","journal-title":"Immunol. Lett."},{"issue":"6","key":"10.1016\/j.ijbiomac.2024.136477_bb0120","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1007\/s40120-023-00541-1","article-title":"Immunotherapies targeting amyloid and tau protein in Alzheimer\u2019s disease: should we move away from diseases and focus on biological targets? A systematic review and expert opinion","volume":"12","author":"Esquer","year":"2023","journal-title":"Neurol. Ther."},{"issue":"35","key":"10.1016\/j.ijbiomac.2024.136477_bb0125","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.2174\/0113816128274618231105173031","article-title":"Recent updates on the development of therapeutics for the targeted treatment of Alzheimer\u2019s disease","volume":"29","author":"Rajput","year":"2023","journal-title":"Curr. Pharm. Des."},{"issue":"22","key":"10.1016\/j.ijbiomac.2024.136477_bb0130","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1016\/j.cell.2023.09.023","article-title":"Accelerating Alzheimer\u2019s therapeutic development: the past and future of clinical trials","volume":"186","author":"Boxer","year":"2023","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.ijbiomac.2024.136477_bb0135","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.biologicals.2011.05.004","article-title":"Biochemical and biological characteristics of cross-reacting material 197 CRM197, a non-toxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications","volume":"39","author":"Broker","year":"2011","journal-title":"Biologicals"},{"issue":"20","key":"10.1016\/j.ijbiomac.2024.136477_bb0140","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1016\/j.vaccine.2016.03.055","article-title":"Carrier priming effect of CRM197 is related to an enhanced B and T cell activation in meningococcal serogroup A conjugate vaccination. Immunological comparison between CRM197 and diphtheria toxoid","volume":"34","author":"Pecetta","year":"2016","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.ijbiomac.2024.136477_bb0145","article-title":"Epitope mapping of the diphtheria toxin and development of an ELISA-specific diagnostic assay","volume":"9","author":"De-Simone","year":"2021","journal-title":"Vaccines (Basel)."},{"issue":"3","key":"10.1016\/j.ijbiomac.2024.136477_bb0150","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1471-4159.2005.03407.x","article-title":"Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer\u2019s disease","volume":"95","author":"Barghorn","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ijbiomac.2024.136477_bb0155","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1750-1326-4-14","article-title":"The PI3K-Akt-mTOR pathway regulates Abeta oligomer induced neuronal cell cycle events","volume":"4","author":"Bhaskar","year":"2009","journal-title":"Mol. Neurodegener."},{"issue":"12","key":"10.1016\/j.ijbiomac.2024.136477_bb0160","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/protein\/gzz010","article-title":"Recombinant production and purification of the human protein tau","volume":"31","author":"Ferrari","year":"2018","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.ijbiomac.2024.136477_bb0165","first-page":"2018","author":"Case","year":"2018","journal-title":"Amber"},{"issue":"8","key":"10.1016\/j.ijbiomac.2024.136477_bb0170","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","article-title":"ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB","volume":"11","author":"Maier","year":"2015","journal-title":"J. Chem. Theory Comput."},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.136477_bb0175","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1063\/1.445869","article-title":"Comparison of simple potential functions for simulating liquid water","volume":"79","author":"Jorgensen","year":"1983","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.ijbiomac.2024.136477_bb0180","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0021-9991(77)90098-5","article-title":"Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes","volume":"23","author":"Ryckaert","year":"1977","journal-title":"J. Comput. Phys."},{"key":"10.1016\/j.ijbiomac.2024.136477_bb0185","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.pep.2016.01.012","article-title":"High-level expression and purification of the major house dust mite allergen Der p 2 in Escherichia coli","volume":"121","author":"Cao","year":"2016","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.ijbiomac.2024.136477_bb0190","first-page":"5565671","article-title":"Endoplasmic reticulum stress is involved in glucocorticoid-induced apoptosis in PC12 cells","volume":"2021","author":"Yi","year":"2021","journal-title":"Anal. Cell. Pathol. (Amst.)"},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.136477_bb0195","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ymthe.2016.10.002","article-title":"Comparison of efficacy of preventive and therapeutic vaccines targeting the N terminus of beta-amyloid in an animal model of Alzheimer\u2019s disease","volume":"25","author":"Petrushina","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ijbiomac.2024.136477_bb0200","first-page":"53","article-title":"Morris water maze test for learning and memory deficits in Alzheimer\u2019s disease model mice","author":"Bromley-Brits","year":"2011","journal-title":"J. Vis. Exp."},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.136477_bb0205","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/nprot.2006.116","article-title":"Morris water maze: procedures for assessing spatial and related forms of learning and memory","volume":"1","author":"Vorhees","year":"2006","journal-title":"Nat. Protoc."},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.136477_bb0210","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12974-020-01744-1","article-title":"Zerumbone ameliorates behavioral impairments and neuropathology in transgenic APP\/PS1 mice by suppressing MAPK signaling","volume":"17","author":"Li","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.ijbiomac.2024.136477_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111585","article-title":"Development of novel theranostic agents for in vivo amyloid imaging and protective effects on human neuroblastoma cells","volume":"181","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2024.136477_bb0220","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b158","article-title":"Alzheimer\u2019s disease","volume":"338","author":"Burns","year":"2009","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.136477_bb0225","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.clinthera.2023.01.011","article-title":"New drug capsule: lecanemab-irmb","volume":"45","author":"Beninger","year":"2023","journal-title":"Clin. Ther."},{"issue":"7943","key":"10.1016\/j.ijbiomac.2024.136477_bb0230","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/d41586-023-00030-3","article-title":"FDA approves Alzheimer\u2019s drug lecanemab amid safety concerns","volume":"613","author":"Reardon","year":"2023","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ijbiomac.2024.136477_bb0235","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jagp.2024.01.013","article-title":"Immunotherapy in Alzheimer\u2019s disease: from the bench to the bedside","volume":"32","author":"Diniz","year":"2024","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.ijbiomac.2024.136477_bb0240","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1126\/science.adj9255","article-title":"Golde AIL: immunotherapies for Alzheimer\u2019s disease","volume":"382","author":"Todd","year":"2023","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.136477_bb0245","article-title":"Alzheimer\u2019s disease drug development pipeline: 2023","volume":"9","author":"Cummings","year":"2023","journal-title":"Alzheimers Dement (N Y)."},{"issue":"3","key":"10.1016\/j.ijbiomac.2024.136477_bb0250","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcad175","article-title":"Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer\u2019s disease","volume":"5","author":"Liu","year":"2023","journal-title":"Brain Commun."},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.136477_bb0255","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3233\/ADR-230025","article-title":"Antibody-mediated clearance of brain amyloid-beta: mechanisms of action, effects of natural and monoclonal anti-abeta antibodies, and downstream effects","volume":"7","author":"Loeffler","year":"2023","journal-title":"J. Alzheimers Dis. Rep."},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.136477_bb0260","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1038\/s41467-020-18525-2","article-title":"Chiral gold nanoparticles enantioselectively rescue memory deficits in a mouse model of Alzheimer\u2019s disease","volume":"11","author":"Hou","year":"2020","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.ijbiomac.2024.136477_bb0265","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/alzrt278","article-title":"First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer\u2019s disease model","volume":"6","author":"Kontsekova","year":"2014","journal-title":"Alzheimers Res. Ther."},{"issue":"Suppl. 1","key":"10.1016\/j.ijbiomac.2024.136477_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1469-0691.12320","article-title":"Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults","volume":"19","author":"Durando","year":"2013","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ijbiomac.2024.136477_bb0275","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1749-6632.2012.06673.x","article-title":"Development and clinical evaluation of Prevnar 13, a 13-valent pneumocococcal CRM197 conjugate vaccine","volume":"1263","author":"Gruber","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813024072866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813024072866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:02:46Z","timestamp":1782900166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813024072866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":55,"alternative-id":["S0141813024072866"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.136477","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CRM197-scaffolded vaccines designed by epitope grafting ameliorate cognitive decline in an Alzheimer's disease model","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.136477","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"136477"}}